Abstract:Abstract Psoriasis affects 2% of the UK population and is associated with significant costs for individuals and society, along with multiple comorbidities including psoriatic arthritis, cardiometabolic disease, and anxiety and depression. Most psoriasis is managed in the community; however, there is wide variation in assessment, diagnosis, treatment and secondary care referral pathways. We sought to evaluate the extent of psoriatic disease managed in the community, primarily under primary care. The aims of the study were to describe the clinical pattern of psoriasis in the community, to describe the burden of psoriatic disease comorbidities, and to explore why patients with severe psoriasis are not referred to secondary care. Participants were recruited over a 1-week period from a pop-up walk-in dermatology clinic run by dermatologists and rheumatologists in a city centre. Individuals who suspected they had psoriasis were invited to approach the study team. The presence or absence of psoriasis was then confirmed by a dermatologist. If psoriasis was confirmed, patients completed questionnaires including medical history, psoriasis treatment, Dermatology Life Quality Index (DLQI), Patient Health Questionnaire 9 (PHQ-9), Patient Needs Questionnaire 9, and Psoriasis Epidemiology Screening Tool (PEST). Clinical examination was documented using Psoriasis Area and Severity Index (PASI), body surface area and Physician’s Global Assessment. Statistical analyses were performed using RStudio (R Foundation, Vienna, Austria). Of > 300 patients screened, 140 were confirmed to have psoriasis. Overall, 46% (65) were male, the mean body mass index was 28.2 kg m−2, and 19% (26) currently smoked. Most (92%) had plaque psoriasis; 36% had concurrent nail involvement. The mean PASI was 4.6, with 34% (48) having a PASI > 5. The commonest comorbidities were cardiovascular disease (41%), depression (31%), anxiety (29%) and psoriatic arthritis (9%). Patients reported significant psychosocial impact, with a mean DLQI of 8.5, and 34% (48) scoring > 11 (severe or very severe impact). Similarly, the mean PHQ-9 was 8.1, with 35% (49) of patients scoring > 9 (moderate or severe depressive symptoms). In total, 73.6% were dissatisfied with their care, the commonest reason being lack of general practitioner appointments (31%). The team suggested a change of topical therapy to 84% (118) of patients and felt 29% (41) required referral to secondary care dermatology, including three urgent referrals. This study demonstrates a high prevalence of undertreated psoriasis in the community and the significant psychosocial impact of the participants’ skin disease. Going forward, improved communication between primary and secondary care services can enhance care for patients with psoriasis. Collaborative working between allied specialties, as demonstrated, can enhance research output and optimize patient outcomes. The research is supported by the NIHR infrastructure. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

Redefining Disease Severity with Special Area Involvement and Reflecting on Treatment Patterns in a Real-World Psoriasis Population

Psoriasis Involving Special Areas is Associated with Worse Quality of Life, Depression, and Limitations in the Ability to Participate in Social Roles and Activities

Updates on Psoriasis in Special Areas

An observational study on treatment regimens and effectiveness for psoriasis in real-world settings among 407 patients in Southeast China

O12 Community Psoriasis: Phenotype and Comorbidity Assessment (COPPACA): an observational study of the prevalence, phenotype and health burden of psoriasis in the community

Burden of Topical Treatments in Psoriasis and Preferred Criteria of Choice: A Survey-Based Evaluation of Patients in Europe

Treatment burden and the perspectives of patients with psoriasis using topical treatments: results from a national survey of adults with psoriasis in the United States

Characterization of psoriasis patients in special body areas: real-world evidence from the Chinese Psoriasis Standardized Diagnosis and Treatment Center

Defining disease severity in atopic dermatitis and psoriasis for the application to biomarker research- an inter-disciplinary perspective

Psoriasis in difficult to treat areas: treatment role in improving health-related quality of life and perception of the disease stigma

Expert Recommendations on Treating Psoriasis in Special Circumstances (Part II)

Factors Associated With Treatment Escalation for Psoriasis: An Analysis of Electronic Health Records Data

Influence of Clinical and Psychosocial Factors on the Adherence to Topical Treatment in Psoriasis

Current challenges and emerging drug delivery strategies for the treatment of psoriasis

Under-Treatment of Patients with Moderate to Severe Psoriasis in the United States: Analysis of Medication Usage with Health Plan Data

Disease burden and quality of life in patients with moderate‐to‐severe psoriasis stratified according to previous systemic treatment exposure

Linkage between patients' characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry

Innovative Approaches in Psoriasis Management: Integration of Novel Drug Delivery Systems, Herbal Medicine, and Lifestyle Modifications

The Global, Regional, and National Burden of Psoriasis: Results and Insights From the Global Burden of Disease 2019 Study

Development of Psoriasis Assessment Tools Among Patients in the CorEvitas Psoriasis Registry

Real world insights for psoriasis: the association of severity of skin lesions with work productivity, medical consumption costs and quality of life